THIS SHARE WILL BE WORTH 3.00 IN 2009

For full article see link.
Could see several smaller biotechnology companies, taken over in the next year.
Hopefully PTI will be looked at for more dual licencing, and not a takeover.


The Times December 05, 2006
Big hole in development pipeline
Robin Pagnamenta: Analysis

Pfizers pipeline was already viewed as weak, but the company now has little choice but to use some of its $17 billion cash pile to acquire other companies and potential drug candidates.

However, competition is likely to be intense as several other big drug groups are facing similar problems at the moment. AstraZeneca, GlaxoSmithKline and others are keen to make acquisitions and are paying big premiums for interesting biotechnology companies.

http://www.timesonline.co.uk/newspaper/0,,2740-2487079,00.html.

Whichever way it goes it's good news for companies like PTI.

Results out.

Apart from the odd hiccup, which investors in companies such as Protherics, should expect, the future looks very rosy indeed.

Three agreements to expand its development pipeline in its core franchises of critical care and cancer. Placing and Open Offer (the 'Placing and Open Offer'), at an issue price of 65 pence per share.
The Overview of the Transactions, looks good, lets hope the offer is nicely priced.
Revenue increased slightly. R@D increased vastly.
Strong cash position at end of period of 17.9 million.
Soon know how the market looks at it. The institutions may bide their time or step in prior to any placing. Would be nice to see them increase their holdings via the placing and before.

Re the cash call.

Whenever I see a company looking for further funding, I pay great detail to the reason.
If it is just to keep the company afloat, then usually it's a bad call.
Protherics are cash sound, so any increased funding in those circumstances is for a sound reason. It is not required for survival.
In my opinion, this cash call is for a very good reason, increased R@D and to push production and sales of existing products.
PTI have a very good product base already earning. They also have an excellent cache of products in varying stages of development, many being fated by the big companies that are looking to increase their product base.
The cash call IS fairly large with a proposed share issue of about 1 fifth of the total shares already in issue.
This to me says they are looking at a bigger picture of development for the next 2 to 5 years.
Yes, of course the shares will be diluted, but if the issue is set to us private investors at a good offer ratio, it may not drop the sp too much, after of course allowing for the dilution sp reduction.
Protherics management has shown consistently good management skills for many years now and as a holder of this share for a considerable time, I have faith in their decisions.
This faith is not blind, it is there because they have given me no reasons to doubt. I doubt that they will be looking at further calls for 2007-2008, as they have presumably judged the amount required with this call to see them through at least the next 2 to 3 years.
I am looking at a steady sp for the coming year.
I am then looking at a steady climbing sp at end 2007, into 2008.
The above is obviously my opinion, so could be totally wrong.
Greek.

Seems sound to me greekman.

Queen1,

Lets hope the market over the next few weeks takes the same view as we have.

Greekman - I hope you are right I am losing my nerve.
I wil support the new shares - lets face it 65p must be rock bottom but I am getting scared. Keep the fath.

Hang inthere transco. Fortune favours the brave, and all the jazz!

Hope I am not jinxing the sp but with an increase of 3.99% on an average volume, against a sector increase of .03%, there may be another after market close release re institutional buying. Can't see any other reason for it to be climbing.

In the cash call statement it stated that one of the reasons was a "Proposed In-licensing of intellectual property from Glenveigh
Pharmaceuticals LLC".

Note the word PROPOSED.

In an article released 2:57 PM CST Thursday in The Nashville Business Journal it states.

The company also has signed licensing deals with Glenveigh Pharmaceuticals, a North Carolina company that focuses on pregnancy-related drugs, and Advanced In Vitro Cell Technologies (AdvanCell), a company headquartered in Spain that develops cancer drugs.

Note. HAS SIGNED.

Maybe this is just a play on words by T N J, but I am wondering if this is part of the reason for the sp rise.
For the full article see link.

http://charlotte.bizjournals.com/nashville/stories/2006/12/04/daily29.html

A good 5 minute read. It shows the way the big drug conglomerates are courting the small bio companies.
Protherics is not mentioned, but must be up there in the sights of those multi million companies.
Licencing deals look the way forward.

Large pharmaceutical companies piggyback onto research, risk By Stephen Pounds
Palm Beach Post Staff Writer
Sunday, December 10, 2006.

"The big pharmaceutical companies recognize that biotechs are more willing to take risks and do research in areas that are more on the edge of science," said Jim Greenwood, president of the Washington, D.C.-based Biotechnology Industry Organization.

While Big Pharma's own drug discovery dwindles, investors in these behemoth companies worry about where sales will come from when a locker full of major medicines loses patent protection. Once the patents expire, drugs are quickly copied for generic sale by companies such as Miami's Ivax Corp., recently acquired by Israel's Teva Pharmaceutical Industries.

And it's not just Pfizer. Merck & Co.'s Fosamax, its $3 billion treatment for slowing bone loss, comes off patent in 2008; Singulair, the $3 billion drug for controlling chronic asthma, in 2010. Bristol-Myers Squibb loses the anti-clotting drug Plavix, the second largest-selling drug globally, in 2011. And Eli Lilly & Co. will lose exclusivity for Zyprexa, a schizophrenia drug worth $4 billion in annual sales, that same year, said Arthur Wong, an analyst with Standard & Poor's.

That's why Big Pharma mainly targets biotech companies, which have garnered a reputation for nimble scientific discovery.

For full article see link.

http://www.palmbeachpost.com/business/content/business/epaper/2006/12/10/a1f_bigpharma_1210.html

Just sent off a large cheque to take up my rights - I hope we come good!!

More sells than buys, on a narrow spread and up 3.25p (4.3%) against the sector (down around 4%). Someone accumulating for an institution increase perhaps.
Can't read anything else into Level 2.

PTI tipped in Money Observer supplement '2007 Wealth Creation Guide'. Under 'Shares Tipped For Big Gains in 2007' Mark Barnett of Invesco Perpetual says:-

"Protherics (PTI) 69p - This small biotech firm has seen share price falls due to delays in pipeline products. But a tie-up with AstraZeneca is worth the entire market capitalisation alone, so the rest of the business is being offered for zero value"

Let's hope he is right.

Well thats it for me pre Xmas, off out.
Merry Xmas to all.
Greek.

Merry Xmas greekman.

Mrry Christmas everyone lets hope 2007 is the year for Protherics its taken a long long time but we are looking good at long last.
I hope everyone went for the offer?

Level 2 looking good for a strong finish.
Order book showing buys to sells 2 to 1.
The spread is very minuscule, in fact as I type it was nil for a mili second.
Volume better than average but nothing fantastic.
Perhaps its the usual ( someone knows something us PI's don't).
A big buy order to fill perhaps!!!!!

No I think its just press comment on the cancer drug.
Although a cure for cancer would be something for now I would be happy with a bit of share price stability.
The offer didnt go that good with only 80% take up I wonder what the usual take up is for a similar offer??? Anyone has any idea?
Big day monday me thinks.

Transco,

I feel the offer went well considering the timing (Xmas and all that), and have no doubt the institutions will eagerly take up any slack.
Looks like the RNS re Digifab will keep this share up, although it was expected.

Well after the re submitting of Voraxaze license application to the US, it was probably a forgone conclusion that the same would be required to Europe (don't we always follow). So on the whole it has to be taken as good news. The US have excepted the fast tracking principal and again presumably Europe will follow.
I was surprised the other day to find that the FDA in 2006 only authorized the full licencing of 15 prescription drugs, their lowest ever. It shows how the drug licencing authorities are toughening up. Its the US follow my lead that to me looks very very promising. Protherics imho looks an even better medium to long term prospect.